Skip to main content
. 2020 Apr 10;47(6):569–577. doi: 10.1111/1346-8138.15343

Figure 2.

Figure 2

Median (IQR) (a) PASI and (b) DLQI scores and patient distribution of brodalumab dose and dosing interval at baseline, day 1, week 28 and week 108. DLQI, Dermatology Life Quality Index; IQR, interquartile range; PASI, Psoriasis Area and Severity Index; Q2W, every 2 weeks; Q4W, every 4 weeks.